1.
|
Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: EFC6596, EUDRACT: 2006-003086-14, NCT00417209
|
|
2.
|
Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: EFC6668, EUDRACT: 2007-001943-23, NCT00625664
|
|
3.
|
Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: TCD6511, EudraCT:2006-006474-21, NCT00327743
|
|
4.
|
Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: EFC6088, XRP9881B/2001, EUDRACT : 2004-000572-14, NCT00087958
|
|
5.
|
Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: TCD6595, XRP9881, NCT00386685
|
|
6.
|
Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: TCD10037, XRP9881, NCT00387907
|
|
7.
|
Phase: Phase II Type: Treatment Status: Completed Age: 18 to 75 Sponsor: Pharmaceutical / Industry Protocol IDs: EFC10073, EudraCT 2006-006473-24, NCT00485979
|
|
8.
|
Phase: Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Protocol IDs: CAN-NCIC-IND101, NCI-V96-1096, IND101
|